| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 81514 |
|
4,563 |
4,193 |
$921K |
| 87481 |
|
5,759 |
1,245 |
$155K |
| 87529 |
|
4,211 |
2,054 |
$123K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
6,055 |
979 |
$116K |
| 87662 |
|
1,475 |
779 |
$72K |
| 87799 |
|
1,008 |
386 |
$51K |
| 87511 |
|
921 |
905 |
$24K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
141 |
139 |
$24K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
411 |
375 |
$22K |
| 87512 |
|
405 |
400 |
$15K |
| 80349 |
|
1,425 |
1,325 |
$15K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
90 |
67 |
$6K |
| 80183 |
|
329 |
261 |
$3K |
| 83698 |
|
94 |
94 |
$3K |
| 80177 |
|
266 |
228 |
$3K |
| 87563 |
|
70 |
69 |
$2K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
36 |
14 |
$300.00 |